Has Atrasentan been included in the relevant policies of medical insurance?

Atrasentan, as an endothelin receptor antagonist, is mainly used to treat endothelin-related diseases, such as primary immunoglobulin A nephropathy. It has achieved positive clinical results by reducing the effect of endothelin, improving kidney function and slowing kidney damage.

In China, atrasentan is already on the market, but due to its relatively short approval time, it has not yet been fully included in the scope of medical insurance reimbursement. Medical insurance reimbursement policies for this new class of drugs usually require a series of review procedures, including analysis of the drug's market performance, efficacy and cost-benefit. Although the efficacy of atrasentan in certain disease areas has been verified, its current price may be high, and its use on the market is still gradually increasing, so the approval process for medical insurance is still in progress.

In addition, the medical insurance coverage of atrasentan is also affected by the National Medical Insurance Administration and relevant policy departments. Specific inclusion policies will be based on an assessment of the drug's clinical need and social benefit. Globally, the medical insurance policies of atrasentan in other countries and regions also vary. Some countries have begun to include it in the medical insurance directory, but in other regions, it is still waiting for approval.

For patients, the current price of atrasentan may pose a certain burden to patients with poor financial status. Nonetheless, as clinical evidence continues to accumulate and market demand increases, atrasentan may be gradually included in the medical insurance systems of more countries in the future, especially for high-risk patients with primary immunoglobulin A nephropathy, which will help reduce treatment costs and improve treatment availability.

In general, atrasentan's medical insurance policy in China has not yet been fully implemented, but with the promotion of its clinical application and the verification of drug effectiveness, it may be included in medical insurance in the future.

Reference materials:https://www.vanrafia.com/